These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 37523320)

  • 1. Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: A retrospective US claims database analysis.
    Yang J; Boytsov N; Carlson JJ; Barthold D
    J Manag Care Spec Pharm; 2023 Aug; 29(8):917-926. PubMed ID: 37523320
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States.
    Sanchez L; Chari A; Cheng M; Cherepanov D; DerSarkissian M; Huang F; Stull DM; Dabora J; Young M; Noga SJ; Pi S; Zhang M; Banatwala A; Duh MS; Ailawadhi S
    J Manag Care Spec Pharm; 2023 Nov; 29(11):1205-1218. PubMed ID: 37776124
    [No Abstract]   [Full Text] [Related]  

  • 3. Health care resource utilization and costs among individuals with vs without Huntington disease in a US population.
    To TM; Exuzides A; Abbass IM; Patel AM; Ta JT; Surinach A; Fuller RLM; Luo J
    J Manag Care Spec Pharm; 2022 Nov; 28(11):1228-1239. PubMed ID: 36282937
    [No Abstract]   [Full Text] [Related]  

  • 4. Practice patterns and outcomes for triple-class exposed patients with relapsed/refractory multiple myeloma in Japan.
    Iida S; Nakakoji M; Spanopoulos D; Okazuka K; Parulekar V; Ishida T
    Future Oncol; 2022 Nov; ():. PubMed ID: 36331578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare Costs Incurred by Patients with Multiple Myeloma Following Triple Class Exposure (TCE) in the US.
    Jagannath S; Joseph N; He J; Crivera C; Fu AZ; Garret A; Shah N
    Oncol Ther; 2021 Dec; 9(2):659-669. PubMed ID: 34694578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Patterns and Outcomes in Triple-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma: Findings From the Multinational ITEMISE Study.
    Dhanasiri S; Hollier-Hann G; Stothard C; Dhanda DS; Davies FE; Rodriguez-Otero P
    Clin Ther; 2021 Nov; 43(11):1983-1996.e3. PubMed ID: 34736769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare resource utilization and cost among patients with type 1 diabetes in the United States.
    Simeone JC; Shah S; Ganz ML; Sullivan S; Koralova A; LeGrand J; Bushman J
    J Manag Care Spec Pharm; 2020 Nov; 26(11):1399-1410. PubMed ID: 33119443
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study.
    Rogers KA; Lu X; Emond B; Côté-Sergent A; Kinkead F; Lafeuille MH; Lefebvre P; Huang Q
    J Manag Care Spec Pharm; 2022 Sep; 28(9):1033-1045. PubMed ID: 35816124
    [No Abstract]   [Full Text] [Related]  

  • 9. Economic and health care resource utilization burden of central nervous system metastases in patients with metastatic melanoma.
    Tawbi H; Bartley K; Seetasith A; Kent M; Lee J; Burton E; Haydu L; McKenna E
    J Manag Care Spec Pharm; 2022 Mar; 28(3):342-353. PubMed ID: 35199578
    [No Abstract]   [Full Text] [Related]  

  • 10. Prolonged oral corticosteroid treatment in patients with systemic lupus erythematosus: An evaluation of 12-month economic and clinical burden.
    Huang SP; DerSarkissian M; Gu YM; Duh MS; Wang MJ; Benson J; Vu J; Averell C; Bell CF
    J Manag Care Spec Pharm; 2023 Apr; 29(4):365-377. PubMed ID: 36989451
    [No Abstract]   [Full Text] [Related]  

  • 11. Healthcare Costs of Multiple Myeloma Patients with Four or More Prior Lines of Therapy, Including Triple-Class Exposure in the United States.
    Jagannath S; Joseph N; He J; Crivera C; Fu AZ; Garrett A; Shah N
    Oncol Ther; 2022 Dec; 10(2):411-420. PubMed ID: 35579821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene-related peptide inhibitors vs other preventive migraine treatments in the United States.
    Varnado OJ; Manjelievskaia J; Ye W; Perry A; Schuh K; Wenzel R
    J Manag Care Spec Pharm; 2022 Aug; 28(8):818-829. PubMed ID: 35876297
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of Weight Change on Economic Outcomes Among Persons with Type 2 Diabetes Mellitus in the United States: Beyond Glycemic Control.
    Karkare S; Fridman M; Dang-Tan T; Lu J; Smolarz BG; DeKoven M; Iyer NN
    J Manag Care Spec Pharm; 2019 Jun; 25(6):658-668. PubMed ID: 30730232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States.
    Zhang X; Beachler DC; Masters E; Liu F; Yang M; Dinh J; Jamal-Allial A; Kolitsopoulos F; Lamy FX
    J Manag Care Spec Pharm; 2022 Feb; 28(2):255-265. PubMed ID: 34854733
    [No Abstract]   [Full Text] [Related]  

  • 15. Burden of illness in progressive fibrosing interstitial lung disease.
    Singer D; Bengtson LGS; Conoscenti CS; Anderson AJ; Brekke L; Shetty SS; Brown KK
    J Manag Care Spec Pharm; 2022 Aug; 28(8):871-880. PubMed ID: 35876293
    [No Abstract]   [Full Text] [Related]  

  • 16. Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States.
    Bell CF; Blauer-Peterson C; Mao J
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1249-1259. PubMed ID: 34165321
    [No Abstract]   [Full Text] [Related]  

  • 17. Health care utilization and costs associated with functional status in patients with psoriatic arthritis.
    Ogdie A; Hwang M; Veeranki P; Portelli A; Sison S; Shafrin J; Pedro S; Hass S; Hur P; Kim N; Yi E; Michaud K
    J Manag Care Spec Pharm; 2022 Sep; 28(9):997-1007. PubMed ID: 36001101
    [No Abstract]   [Full Text] [Related]  

  • 18. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
    Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H
    J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased delay from initial concern to diagnosis of autism spectrum disorder and associated health care resource utilization and cost among children aged younger than 6 years in the United States.
    Vu M; Duhig AM; Tibrewal A; Campbell CM; Gaur A; Salomon C; Gupta A; Kruse M; Taraman S
    J Manag Care Spec Pharm; 2023 Apr; 29(4):378-390. PubMed ID: 36989447
    [No Abstract]   [Full Text] [Related]  

  • 20. Health Care Resource Utilization and Costs in First-Line Treatments for Patients with Metastatic Melanoma in the United States.
    Klink AJ; Chmielowski B; Feinberg B; Ahsan S; Nero D; Liu FX
    J Manag Care Spec Pharm; 2019 Aug; 25(8):869-877. PubMed ID: 30945965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.